Patents by Inventor Greg Delahanty

Greg Delahanty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20150141429
    Abstract: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 21, 2015
    Applicant: EISAI INC.
    Inventors: Weizheng XU, Greg Delahanty, Ling Wei, Jie Zhang
  • PARP inhibitor compounds, compositions and methods of use
    Patent number: 8894989
    Abstract: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly(ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: November 25, 2014
    Assignee: Eisai Inc.
    Inventors: Weizheng Xu, Greg Delahanty, Ling Wei, Jie Zhang
  • Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP
    Patent number: 8883787
    Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: November 11, 2014
    Assignee: Eisai Inc.
    Inventors: Weizheng Xu, Greg Delahanty, Jie Zhang
  • DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP
    Publication number: 20130345225
    Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
    Type: Application
    Filed: June 10, 2013
    Publication date: December 26, 2013
    Applicant: Eisai Inc.
    Inventors: Weizheng XU, Greg Delahanty, jIE ZHANG
  • Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP
    Patent number: 8470825
    Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: June 25, 2013
    Assignee: Eisai Inc.
    Inventors: Weizheng Xu, Greg Delahanty, Jie Zhang
  • PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20130011365
    Abstract: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radio sensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.
    Type: Application
    Filed: June 19, 2012
    Publication date: January 10, 2013
    Applicant: EISAI INC.
    Inventors: Weizheng XU, Greg Delahanty, Ling Wei, Jie Zhang
  • PARP inhibitor compounds, compositions and methods of use
    Patent number: 8236802
    Abstract: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: August 7, 2012
    Assignee: Eisai Inc.
    Inventors: Weizheng Xu, Greg Delahanty, Ling Wei, Jie Zhang
  • DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP
    Publication number: 20120115873
    Abstract: The present invention relates to diazabenzo[de]anthracen-3.-onei compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
    Type: Application
    Filed: September 27, 2011
    Publication date: May 10, 2012
    Applicant: EISAI INC.
    Inventors: Weizheng XU, Greg Delahanty, Jie Zhang
  • Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP
    Patent number: 8058275
    Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: November 15, 2011
    Assignee: Eisai Inc.
    Inventors: Weizheng Xu, Greg Delahanty, Jie Zhang
  • DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP
    Publication number: 20110092478
    Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
    Type: Application
    Filed: October 22, 2010
    Publication date: April 21, 2011
    Applicant: Eisai Inc.
    Inventors: Weizheng Xu, Greg Delahanty, Jie Zhang
  • Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
    Patent number: 7820668
    Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: October 26, 2010
    Assignee: Eisai Inc.
    Inventors: Weizheng Xu, Greg Delahanty, Jie Zhang
  • RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS
    Publication number: 20100056596
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: March 20, 2009
    Publication date: March 4, 2010
    Applicant: Sequoia Pharmaceuticals
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
  • Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol
    Patent number: 7534776
    Abstract: A process for making water-soluble phosphonooxymethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A. In particular, the process for preparing water-soluble phosphonooxymethyl derivatives comprises the steps of: R—OH represents an alcohol- or phenol-containing drug, n represents an integer of 1 or 2, R1 is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation, and R2 is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: May 19, 2009
    Assignee: Eisai Corporation of North America
    Inventors: George Bonneville, Greg Delahanty, Andrew J. Walz
  • PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20090098084
    Abstract: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.
    Type: Application
    Filed: October 2, 2008
    Publication date: April 16, 2009
    Applicant: MGI GP, Inc.
    Inventors: Weizheng Xu, Greg Delahanty, Ling Wei, Jie Zhang
  • Resistance-repellent retroviral protease inhibitors
    Patent number: 7507763
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: March 24, 2009
    Assignee: Sequoia Pharmaceuticals
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
  • Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp
    Publication number: 20090028815
    Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
    Type: Application
    Filed: January 19, 2006
    Publication date: January 29, 2009
    Applicant: MGI GP, INC.
    Inventors: Weizheng Xu, Greg Delahanty, Jie Zhang
  • Resistance-repellent retroviral protease inhibitors
    Patent number: 7378441
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: May 27, 2008
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
  • Process for preparing water soluble phosphonooxymethyl derivatives of alcohol and phenol
    Patent number: 7229978
    Abstract: A process for making water-soluble phosphonooxymethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: June 12, 2007
    Assignee: MGI GP, Inc.
    Inventors: George Bonneville, Greg Delahanty, Andrew J. Walz
  • Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol
    Publication number: 20070043206
    Abstract: A process for making water-soluble phosphonooxymethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A. In particular, the process for preparing water-soluble phosphonooxymethyl derivatives comprises the steps of: R—OH represents an alcohol- or phenol-containing drug, n represents an integer of 1 or 2, R1 is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation, and R2 is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation.
    Type: Application
    Filed: October 26, 2006
    Publication date: February 22, 2007
    Applicant: MGI GP, Inc.
    Inventors: George Bonneville, Greg Delahanty, Andrew Walz
  • Resistance-repellent retroviral protease inhibitors
    Publication number: 20060258627
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: July 21, 2006
    Publication date: November 16, 2006
    Applicant: Sequoia Pharmaceuticals
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Rajendran